Skip Navigation

Randall L. Davis, Ph.D.


Neuroimmune signaling, Drugs of abuse, Mood and Anxiety disorders

Degree: PhD, Nutrition
Broad Expertise/Interests:
  • Neuroinflammation
  • Pharmacology
  • Drugs of abuse
  • Anxiety and Depression
  • Neuroimmune signaling and Obesity
  • In vitro models of neuroinflammation (human astrocytes and microglia)
  • Western blot/Co-IP
  • RT-PCR
  • Cell Migration
  • Mouse model of neuroinflammation
  • Behavioral analysis (mice); sickness, depression, anxiety
Seeking Collaborators with Skill Sets:
  • Access to human tissues (Brain, blood, or CSF)
  • Interests in HIV dementia, CNS disorders, Mood and Anxiety disorders
Neuroscience Research Interests:

Identification and characterization of novel anti-inflammatory agents to be used in the treatment of CNS disorders involving neuroinflammation

Understanding the role of neuroimmune signaling in obesity

Understanding the impact of prescribed medications (antidepressants, antipsychotics, cART on neuroinflammation and/or neurotoxicity

Funding in the Last Three Years:


Publication Highlights:

Davis et al., (2013) Beta-Funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes Neurochem Int 62:478-485.

Davis et al., (2015) The opioid antagonist, beta-funaltrexamine, inhibits NF-kB signaling and chemokine expression in human a and in mice. Eur J Pharmacol 762:193-201.

Davis et al., The opioid antagonis,beta-funaltrexamine, inhibits lipopolysaccharide-induced neuroinflammation and reduces sickness behavior in mice. Physio Behav 173:52-60.